Provided by Tiger Trade Technology Pte. Ltd.

Natera

225.49
-1.9100-0.84%
Post-market: 225.34-0.1500-0.07%17:41 EST
Volume:1.85M
Turnover:415.66M
Market Cap:31.19B
PE:-98.45
High:228.38
Open:227.79
Low:221.84
Close:227.40
52wk High:246.90
52wk Low:125.38
Shares:138.32M
Float Shares:135.00M
Volume Ratio:1.59
T/O Rate:1.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2905
EPS(LYR):-1.5269
ROE:-29.02%
ROA:-12.89%
PB:24.91
PE(LYR):-147.68

Loading ...

Natera Inc. Director Herm Rosenman Reports Disposal of Common Shares

Reuters
·
Yesterday

Natera Study Shows Signatera Predicts Recurrence Risk in Early-Stage Breast Cancer

Reuters
·
Dec 16

Natera Is Maintained at Overweight by JP Morgan

Dow Jones
·
Dec 16

Natera Drops Appeal in Patent Dispute With NeoGenomics

Reuters
·
Dec 15

Natera (NTRA): Assessing Valuation After Strong Multi‑Year Share Price Rally

Simply Wall St.
·
Dec 15

Natera and MEDSIR Launch MiRaDoR Trial in HR+/HER2- Breast Cancer

Reuters
·
Dec 12

Natera and Medsir to Collaborate on the Mirador Trial in Breast Cancer

THOMSON REUTERS
·
Dec 12

Natera Reports Signatera MRD Test Predicts Recurrence Risk in Early-Stage HR+/HER2- Breast Cancer

Reuters
·
Dec 11

BRIEF-Natera Files For Offering Of Up To 1.95 Mln Shares Of Common Stock By Selling Stockholders

Reuters
·
Dec 10

Natera Inc Files for Offering of up to 1.95 Mln Shares of Common Stock by Selling Stockholders - SEC Filing

THOMSON REUTERS
·
Dec 10

Director Rowan E. Chapman Reports Disposal of Natera Inc. Common Shares

Reuters
·
Dec 10

Natera Reports ctDNA Testing Predicts Lymphoma Outcomes in Major Clinical Studies

Reuters
·
Dec 09

Natera Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Dec 09

Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?

Benzinga_recent_news
·
Dec 06

BRIEF-Natera Acquires Foresight Diagnostics

Reuters
·
Dec 05

Natera Acquires Foresight in $275 Million All-Stock Deal

Reuters
·
Dec 05

Natera Inc: Closed Deal in All-Stock Transaction of $275 Mln Upfront & Additional $175 Mln in Earnouts

THOMSON REUTERS
·
Dec 05

Natera President of Clinical Diagnostics Solomon Moshkevich Reports Sale of Common Shares

Reuters
·
Dec 04

Natera CEO and President Steven Leonard Chapman Reports Disposal of Common Shares

Reuters
·
Dec 04

Natera Unveils New Signatera Data Showing Superior Lymphoma Recurrence Detection at ASH 2025

Reuters
·
Dec 03